Medical Research News and Research

RSS

CXCL5 molecule causes insulin resistance and type 2 diabetes in obese people

Many people who are overweight or obese develop insulin resistance and type 2 diabetes at some stage in their lives. A European research team has now discovered that obese people have large amounts of the molecule CXCL5, produced by certain cells in fatty tissue.

25 Nov 2009

LRI awards $3.6 million grants to drive innovative science in lupus and related diseases

The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.

24 Nov 2009

JDRF partners with the Canadian Government in diabetes research

Juvenile Diabetes Research Foundation (JDRF) Canada is pleased to announce its first partnership with the Government of Canada through the Federal Economic Development Agency of Southern Ontario. Through this innovative two-year partnership, the Government of Canada is committing $20 million and JDRF is making a matching contribution of $10 million to accelerate world-class diabetes research in Southern Ontario by implementing a clinical trial network for diabetes research.

23 Nov 2009

Alcohol consumption in pregnancy affects child behaviour in different ways: Study

A new study from Perth's Telethon Institute for Child Health Research has found evidence that the amount and timing of alcohol consumption in pregnancy affects child behaviour in different ways.

23 Nov 2009

Six outstanding contributors to health and medical research industry recognised

Six outstanding contributors to the health and medical research industry are being recognised by Research Australia in its annual "Thank You" Day awards tomorrow (Friday 20 November 2009).

20 Nov 2009

NIEHS grants $13 million for engineered nanomaterials research

The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, is increasing its investment in understanding the potential health, safety and environmental issues related to tiny particles that are used in many everyday products such as sunscreens, cosmetics and electronics. The NIEHS will award about $13 million over a two-year period, through the American Recovery and Reinvestment Act, to bolster the NIEHS's ongoing research portfolio in the area of engineered nanomaterials (ENMs).

20 Nov 2009

University of Leeds scientists' discovery could lead to new treatment route for BSE and CJD

A new treatment route for bovine spongiform encephalopathy (BSE) and its human form Creutzfeldt Jakob disease (CJD) could be a step closer thanks to a discovery by scientists at the University of Leeds.

20 Nov 2009

New technology to investigate sleep disorders developed

Virtanen has developed a method for analysing snoring sounds by using a PC with a microphone connection and a wireless microphone. The objective was to create an application that could be used at home to monitor snoring. By utilizing this technology, researchers from Tampere University of Technology and the University of Helsinki have investigated sleep disorders and further refined related screening technologies.

19 Nov 2009

BIMR wins a GO grant from the National Institute of Mental Health

Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).

19 Nov 2009

New mathematical model may hasten drug development for Parkinson's Disease

Australian scientists have significantly advanced our understanding of dopamine release from nerve cells, findings that should speed the development of more effective drugs for treating Parkinson's Disease.

19 Nov 2009

Review of the results of Phase 2b clinical trial on PASCAL announced

ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.

18 Nov 2009

CTSA institutions receive NIH grants to study drug safety and efficacy in children

Studying drugs in pediatric populations is challenging because drugs often affect children differently than they do adults. The scarcity of pediatric studies limits the ability of doctors and scientists to predict drug dosing, safety and efficacy in children. To address this gap, the National Institutes of Health announced today 18 grants to help determine outcome measures and increase the likelihood of success of future trials of treatments for children.

18 Nov 2009

Global Alliance for Chronic Diseases announces targets

The Global Alliance for Chronic Diseases (GACD) on Monday outlined plans "to invest tens of millions of dollars in heart and lung disease studies in a battle against a global epidemic of chronic disease," over five years, Reuters reports.

17 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

Recent developments at Burnham Institute for Medical Research

New antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) and other pesky bacteria. Andrei Osterman and collaborators have used comparisons of bacterial genomes to identify new targets for antibiotics and produced first-generation chemical inhibitors of a class of bacterial enzymes, called NadDs (nicotinate mononucleotide adenylyltransferases).

17 Nov 2009

New insights into cells' reaction to DNA damage

Cancer researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have gained new insights into how cells react to DNA damage. Dr. Michael Stilmann, Dr. Michael Hinz and Professor Claus Scheidereit have shown that the protein PARP-1, which detects DNA damage within seconds, activates the transcription factor NF-kappaB, a well-known regulator of gene expression.

17 Nov 2009

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

An alliance of institutions collectively managing an estimated 80 percent of all public health research funding worldwide today announced their first targets for concerted action in the fight against "chronic non-communicable diseases" (CNCDs).

17 Nov 2009

Talend bags orders from several global healthcare customers

Talend, the recognized market leader in open source data integration software, today announced several global healthcare customer wins including Children’s Hospital & Medical Center of Omaha, Hosta, The Clermont-Ferrand Hospital and The University for Health Sciences, Medical Informatics and Technology (UMIT). The traction gained in this space further validates Talend’s ability to provide scalable and flexible solutions at an affordable cost to healthcare organizations of all sizes, while satisfying the need for the real-time data the industry demands.

16 Nov 2009

Myeloma UK launches innovative clinical trial network

Yorkshire myeloma patients are set to be among the first to benefit from an innovative Myeloma Clinical Trial Network launched by Myeloma UK.

16 Nov 2009

Normal synaptic activity in nerve cells protects brain from Huntington's disease

Investigators at Burnham Institute for Medical Research (Burnham), the University of British Columbia's Centre for Molecular Medicine and Therapeutics and the University of California, San Diego have found that normal synaptic activity in nerve cells (the electrical activity in the brain that allows nerve cells to communicate with one another) protects the brain from the misfolded proteins associated with Huntington's disease.

16 Nov 2009